NCCN Receives $2 Million Grant from Pfizer

Funding will support innovative cancer research

JENKINTOWN, Pa., September 5, 2006 — The National Comprehensive Cancer Network (NCCN) and Pfizer, Inc., have entered into a collaboration to conduct research on the oral multikinase inhibitor sunitinib (Sutent), a drug currently approved for advanced renal cell carcinoma and gastrointestinal stromal tumors. Sutent is being studied in a broad range of solid tumors.

“NCCN’s goal is to improve the quality, effectiveness and efficiency of oncology practice. One way this is accomplished is through facilitating research partnerships,” said William T. McGivney, Ph.D., Chief Executive Officer, NCCN. “This grant from Pfizer supports basic and clinical research designed and carried out by investigators at NCCN member institutions with the overall goal of improving patient survival and quality of life.”

The Oncology Research Program (ORP) facilitates all phases of clinical research by identifying clinical investigators and initiating trials at NCCN member institutions. The ORP draws on the expertise of investigators at 20 of the world’s leading cancer centers and helps to establish collaborations with pharmaceutical and biotech companies.

“We are very happy to support this key research in collaboration with NCCN,” said Sakina Hoosen, M.D., Team Leader, US Medical Oncology, Pfizer, Inc. “Our goal is not only to advance clinical research, but also to provide the best possible treatment options to improve survival for all patients with cancer.”